Mount Sinai teams with PinkStar on breast MRI AI

PinkStar has signed a data and collaboration agreement with Mount Sinai Health System to train and validate its breast MRI AI technology on real-world clinical data. The partnership is meant to improve interpretation, support earlier cancer detection and address a gap in AI tools for breast MRI.

Why it matters: - Breast MRI is the most sensitive imaging test for finding breast cancer, but it is also one of the hardest and most time-consuming to interpret. - AI tools are already common in mammography and ultrasound, but breast MRI has lacked comparable decision support. - The collaboration could help radiologists identify suspicious findings earlier, improve consistency and reduce unnecessary biopsies.

What happened: - PinkStar announced a Data and Collaboration Agreement with Mount Sinai Health System on August 11, 2026. - The agreement gives PinkStar access to clinical data to power and train its breast MRI AI technology. - The technology was developed at Sheba Medical Center through its ARC innovation arm. - The partnership is PinkStar’s first clinical collaboration with a leading U.S. academic medical institution. - Mount Sinai is making a long-term commitment to advancing the technology.

The details: - PinkStar develops decision-support software for breast MRI. - The system is designed to assist radiologists at the point of MRI reading. - The software characterizes suspicious findings and is aimed at supporting detection of early-stage lesions. - The company says the technology is intended to improve interpretation efficiency and consistency across readers. - PinkStar also says the tool could reduce unnecessary biopsies. - The collaboration will be led by Dr. Laurie Margolies, Professor of Radiology at the Icahn School of Medicine at Mount Sinai and Vice-Chair for Breast Imaging, and Dr. Elisa Port, Chief of Breast Surgery at Mount Sinai Health System. - The work will run through the Tisch Cancer Center and its Center of Excellence for Breast Cancer. - PinkStar was co-founded by Sivan Sadan, Dr. Debbie Anaby and Prof. Miri Sklair-Levy. - The company’s technology foundation comes from Sheba Medical Center’s ARC innovation engine. - PinkStar included a company website in the release. - Sheba Medical Center included its websites for Sheba Global and ARC Innovation. - Mount Sinai included its health system website.

Between the lines: - The deal gives PinkStar a major U.S. academic partner and access to real-world cases that should help test how the software performs outside a development setting. - Mount Sinai is extending its AI work from mammography and ultrasound into breast MRI, where no FDA-cleared AI solution is currently available for interpretation support. - The agreement also signals that breast MRI AI is moving closer to clinical validation, not just early product development. - Both organizations are framing the partnership as a response to a real clinical gap, especially as breast MRI use expands.

What's next: - PinkStar will use Mount Sinai data to train and validate its breast MRI AI system. - The partnership is expected to support further refinement of the technology for clinical use. - If successful, the collaboration could help move breast MRI decision support closer to broader adoption in radiology workflows. - The companies are positioning the work as a step toward earlier and more accurate breast cancer diagnosis.

The bottom line: - PinkStar and Mount Sinai are trying to bring AI to one of breast imaging’s toughest blind spots: breast MRI interpretation.